

Galit Alter

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6071361/publications.pdf>

Version: 2024-02-01

306
papers

33,908
citations

4136

87
h-index

5677

162
g-index

362
all docs

362
docs citations

362
times ranked

36463
citing authors

#	ARTICLE	IF	CITATIONS
1	Measles Vaccination Elicits a Polyfunctional Antibody Response, Which Decays More Rapidly in Early Vaccinated Children. <i>Journal of Infectious Diseases</i> , 2022, 225, 1755-1764.	1.9	3
2	Coronavirus Disease 2019 Messenger RNA Vaccine Immunogenicity in Immunosuppressed Individuals. <i>Journal of Infectious Diseases</i> , 2022, 225, 1124-1128.	1.9	15
3	Serological Markers of SARS-CoV-2 Reinfection. <i>MBio</i> , 2022, 13, e0214121.	1.8	8
4	Innovative vaccine approaches—a Keystone Symposia report. <i>Annals of the New York Academy of Sciences</i> , 2022, 1511, 59-86.	1.8	5
5	mRNA-1273 vaccine-induced antibodies maintain Fc effector functions across SARS-CoV-2 variants of concern. <i>Immunity</i> , 2022, 55, 355-365.e4.	6.6	76
6	Reduction of CD8 T cell functionality but not inhibitory capacity by integrase inhibitors. <i>Journal of Virology</i> , 2022, , JVI0173021.	1.5	2
7	Humoral and cellular immunogenicity of SARS-CoV-2 vaccines in chronic lymphocytic leukemia: a prospective cohort study. <i>Blood Advances</i> , 2022, , .	2.5	14
8	Upper and lower respiratory tract correlates of protection against respiratory syncytial virus following vaccination of nonhuman primates. <i>Cell Host and Microbe</i> , 2022, 30, 41-52.e5.	5.1	44
9	Dissecting Fc signatures of protection in neonates following maternal influenza vaccination in a placebo-controlled trial. <i>Cell Reports</i> , 2022, 38, 110337.	2.9	3
10	Durability of Anti-Spike Antibodies in Infants After Maternal COVID-19 Vaccination or Natural Infection. <i>JAMA - Journal of the American Medical Association</i> , 2022, 327, 1087.	3.8	103
11	SARS-CoV-2 antibodies protect against reinfection for at least 6 months in a multicentre seroepidemiological workplace cohort. <i>PLoS Biology</i> , 2022, 20, e3001531.	2.6	10
12	Cooperation Between Systemic and Mucosal Antibodies Induced by Virosomal Vaccines Targeting HIV-1 Env: Protection of Indian Rhesus Macaques Against Low-Dose Intravaginal SHIV Challenges. <i>Frontiers in Immunology</i> , 2022, 13, 788619.	2.2	4
13	Trends in Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Seroprevalence in Massachusetts Estimated from Newborn Screening Specimens. <i>Clinical Infectious Diseases</i> , 2022, 75, e105-e113.	2.9	3
14	Differential Severe Acute Respiratory Syndrome Coronavirus 2 Antibody Profiles After Allergic Reactions to Messenger RNA Coronavirus Disease 2019 Vaccine. <i>Journal of Infectious Diseases</i> , 2022, 226, 1231-1236.	1.9	1
15	Defining the risk of SARS-CoV-2 variants on immune protection. <i>Nature</i> , 2022, 605, 640-652.	13.7	117
16	Omicron variant Spike-specific antibody binding and Fc activity are preserved in recipients of mRNA or inactivated COVID-19 vaccines. <i>Science Translational Medicine</i> , 2022, 14, eabn9243.	5.8	84
17	Durability and Cross-Reactivity of SARS-CoV-2 mRNA Vaccine in Adolescent Children. <i>Vaccines</i> , 2022, 10, 492.	2.1	9
18	Humoral immune responses against SARS-CoV-2 in transplantation: Actionable biomarker or misplaced trust?. <i>American Journal of Transplantation</i> , 2022, , .	2.6	1

#	ARTICLE	IF	CITATIONS
19	Altered Maternal Antibody Profiles in Women With Human Immunodeficiency Virus Drive Changes in Transplacental Antibody Transfer. <i>Clinical Infectious Diseases</i> , 2022, 75, 1359-1369.	2.9	8
20	A modified vaccinia Ankara vaccine expressing spike and nucleocapsid protects rhesus macaques against SARS-CoV-2 Delta infection. <i>Science Immunology</i> , 2022, 7, eabo0226.	5.6	22
21	A homologous or variant booster vaccine after Ad26.COVS immunization enhances SARS-CoV-2-specific immune responses in rhesus macaques. <i>Science Translational Medicine</i> , 2022, 14, eabm4996.	5.8	13
22	Functional and structural modifications of influenza antibodies during pregnancy. <i>IScience</i> , 2022, 25, 104088.	1.9	7
23	mRNA-1273 and BNT162b2 COVID-19 vaccines elicit antibodies with differences in Fc-mediated effector functions. <i>Science Translational Medicine</i> , 2022, 14, eabm2311.	5.8	100
24	Defining Discriminatory Antibody Fingerprints in Active and Latent Tuberculosis. <i>Frontiers in Immunology</i> , 2022, 13, 856906.	2.2	12
25	Preserved recognition of Omicron spike following COVID-19 messenger RNA vaccination in pregnancy. <i>American Journal of Obstetrics and Gynecology</i> , 2022, 227, 493.e1-493.e7.	0.7	3
26	Serological testing for SARS-CoV-2 antibodies of employees shows low transmission working in a cancer center. <i>PLoS ONE</i> , 2022, 17, e0266791.	1.1	1
27	Defining the determinants of protection against SARS-CoV-2 infection and viral control in a dose-down Ad26.CoV2.S vaccine study in nonhuman primates. <i>PLoS Biology</i> , 2022, 20, e3001609.	2.6	14
28	Correlates of protection against SARS-CoV-2 infection and COVID-19 disease. <i>Immunological Reviews</i> , 2022, 310, 6-26.	2.8	138
29	mRNA vaccine boosting enhances antibody responses against SARS-CoV-2 Omicron variant in individuals with antibody deficiency syndromes. <i>Cell Reports Medicine</i> , 2022, 3, 100653.	3.3	10
30	Maternal immune response and placental antibody transfer after COVID-19 vaccination across trimester and platforms. <i>Nature Communications</i> , 2022, 13, .	5.8	47
31	Antibody Fc characteristics and effector functions correlate with protection from symptomatic dengue virus type 3 infection. <i>Science Translational Medicine</i> , 2022, 14, .	5.8	21
32	The Kinetics of SARS-CoV-2 Antibody Development Is Associated with Clearance of RNAemia. <i>MBio</i> , 2022, 13, .	1.8	10
33	Persistent Maintenance of Intermediate Memory B Cells Following SARS-CoV-2 Infection and Vaccination Recall Response. <i>Journal of Virology</i> , 2022, 96, .	1.5	11
34	Preclinical Immunogenicity and Efficacy of a Multiple Antigen-Presenting System (MAPSTM) SARS-CoV-2 Vaccine. <i>Vaccines</i> , 2022, 10, 1069.	2.1	2
35	Adoptive Transfer of Serum Samples From Children With Invasive Staphylococcal Infection and Protection Against <i>Staphylococcus aureus</i> Sepsis. <i>Journal of Infectious Diseases</i> , 2021, 223, 1222-1231.	1.9	4
36	Liver Fibrosis Index FIB-4 Is Associated With Mortality in COVID-19. <i>Hepatology Communications</i> , 2021, 5, 434-445.	2.0	38

#	ARTICLE	IF	CITATIONS
37	Reply. Journal of Pediatrics, 2021, 228, 320-323.	0.9	0
38	COVID-19-neutralizing antibodies predict disease severity and survival. Cell, 2021, 184, 476-488.e11.	13.5	586
39	Antibodies for Human Immunodeficiency Virus-1 Cure Strategies. Journal of Infectious Diseases, 2021, 223, S22-S31.	1.9	7
40	Discrete SARS-CoV-2 antibody titers track with functional humoral stability. Nature Communications, 2021, 12, 1018.	5.8	82
41	Compromised SARS-CoV-2-specific placental antibody transfer. Cell, 2021, 184, 628-642.e10.	13.5	167
42	Humoral signatures of protective and pathological SARS-CoV-2 infection in children. Nature Medicine, 2021, 27, 454-462.	15.2	137
43	Comorbid illnesses are associated with altered adaptive immune responses to SARS-CoV-2. JCI Insight, 2021, 6, .	2.3	39
44	The multifaceted roles of breast milk antibodies. Cell, 2021, 184, 1486-1499.	13.5	90
45	A modified vaccinia Ankara vector-based vaccine protects macaques from SARS-CoV-2 infection, immune pathology, and dysfunction in the lungs. Immunity, 2021, 54, 542-556.e9.	6.6	72
46	Production of HIV-1 Env-Specific Antibodies Mediating Innate Immune Functions Depends on Cognate Interleukin-21-Secreting CD4 ⁺ T Cells. Journal of Virology, 2021, 95, .	1.5	4
47	Non-neutralizing Antibodies May Contribute to Suppression of SIVmac239 Viremia in Indian Rhesus Macaques. Frontiers in Immunology, 2021, 12, 657424.	2.2	2
48	Persistence of viral RNA in lymph nodes in ART-suppressed SIV/SHIV-infected Rhesus Macaques. Nature Communications, 2021, 12, 1474.	5.8	26
49	A Fc engineering approach to define functional humoral correlates of immunity against Ebola virus. Immunity, 2021, 54, 815-828.e5.	6.6	34
50	Adjuvanting a subunit COVID-19 vaccine to induce protective immunity. Nature, 2021, 594, 253-258.	13.7	253
51	Immunogenicity of the Ad26.COVS Vaccine for COVID-19. JAMA - Journal of the American Medical Association, 2021, 325, 1535.	3.8	260
52	Viral Rebound Kinetics Correlate with Distinct HIV Antibody Features. MBio, 2021, 12, .	1.8	10
53	Tissues: the unexplored frontier of antibody mediated immunity. Current Opinion in Virology, 2021, 47, 52-67.	2.6	21
54	Viral Load Kinetics of Severe Acute Respiratory Syndrome Coronavirus 2 in Hospitalized Individuals With Coronavirus Disease 2019. Open Forum Infectious Diseases, 2021, 8, ofab153.	0.4	20

#	ARTICLE	IF	CITATIONS
55	Distinct clonal evolution of B-cells in HIV controllers with neutralizing antibody breadth. <i>ELife</i> , 2021, 10, .	2.8	16
56	Associations Between Antibody Fc-Mediated Effector Functions and Long-Term Sequelae in Ebola Virus Survivors. <i>Frontiers in Immunology</i> , 2021, 12, 682120.	2.2	9
57	Mining HIV controllers for broad and functional antibodies to recognize and eliminate HIV-infected cells. <i>Cell Reports</i> , 2021, 35, 109167.	2.9	8
58	Antibodies against human endogenous retrovirus K102 envelope activate neutrophils in systemic lupus erythematosus. <i>Journal of Experimental Medicine</i> , 2021, 218, .	4.2	26
59	Protective efficacy of Ad26.COV2.S against SARS-CoV-2 B.1.351 in macaques. <i>Nature</i> , 2021, 596, 423-427.	13.7	40
60	Reduced blood-stage malaria growth and immune correlates in humans following RH5 vaccination. <i>Med</i> , 2021, 2, 701-719.e19.	2.2	73
61	SARS-CoV-2 RBD trimer protein adjuvanted with Alum-3M-052 protects from SARS-CoV-2 infection and immune pathology in the lung. <i>Nature Communications</i> , 2021, 12, 3587.	5.8	71
62	Immunogenicity of Ad26.COV2.S vaccine against SARS-CoV-2 variants in humans. <i>Nature</i> , 2021, 596, 268-272.	13.7	290
63	Comprehensive Data Integration Approach to Assess Immune Responses and Correlates of RTS,S/AS01-Mediated Protection From Malaria Infection in Controlled Human Malaria Infection Trials. <i>Frontiers in Big Data</i> , 2021, 4, 672460.	1.8	8
64	Coordinated Fc-effector and neutralization functions in HIV-infected children define a window of opportunity for HIV vaccination. <i>Aids</i> , 2021, 35, 1895-1905.	1.0	4
65	Memory B cells targeting SARS-CoV-2 spike protein and their dependence on CD4+ T cell help. <i>Cell Reports</i> , 2021, 35, 109320.	2.9	47
66	Immune age and biological age as determinants of vaccine responsiveness among elderly populations: the Human Immunomics Initiative research program. <i>European Journal of Epidemiology</i> , 2021, 36, 753-762.	2.5	9
67	Immunogenicity of COVID-19 mRNA Vaccines in Pregnant and Lactating Women. <i>JAMA - Journal of the American Medical Association</i> , 2021, 325, 2370.	3.8	307
68	Multisystem inflammatory syndrome in children is driven by zonulin-dependent loss of gut mucosal barrier. <i>Journal of Clinical Investigation</i> , 2021, 131, .	3.9	170
69	An intranasal vaccine durably protects against SARS-CoV-2 variants in mice. <i>Cell Reports</i> , 2021, 36, 109452.	2.9	90
70	Ebola vaccine-induced protection in nonhuman primates correlates with antibody specificity and Fc-mediated effects. <i>Science Translational Medicine</i> , 2021, 13, .	5.8	22
71	Proteo-Genomic Analysis Identifies Two Major Sites of Vulnerability on Ebolavirus Glycoprotein for Neutralizing Antibodies in Convalescent Human Plasma. <i>Frontiers in Immunology</i> , 2021, 12, 706757.	2.2	4
72	Evaluation of Three Commercial and Two Non-Commercial Immunoassays for the Detection of Prior Infection to SARS-CoV-2. <i>Journal of Applied Laboratory Medicine</i> , The, 2021, 6, 1561-1570.	0.6	14

#	ARTICLE	IF	CITATIONS
73	Protective antibodies elicited by SARS-CoV-2 spike protein vaccination are boosted in the lung after challenge in nonhuman primates. <i>Science Translational Medicine</i> , 2021, 13, .	5.8	56
74	Antibody Subclass and Glycosylation Shift Following Effective TB Treatment. <i>Frontiers in Immunology</i> , 2021, 12, 679973.	2.2	22
75	Pan-protective anti-alphavirus human antibodies target a conserved E1 protein epitope. <i>Cell</i> , 2021, 184, 4414-4429.e19.	13.5	41
76	HIV Antibody Profiles in HIV Controllers and Persons With Treatment-Induced Viral Suppression. <i>Frontiers in Immunology</i> , 2021, 12, 740395.	2.2	6
77	The autoimmune signature of hyperinflammatory multisystem inflammatory syndrome in children. <i>Journal of Clinical Investigation</i> , 2021, 131, .	3.9	103
78	Therapeutic alphavirus cross-reactive E1 human antibodies inhibit viral egress. <i>Cell</i> , 2021, 184, 4430-4446.e22.	13.5	25
79	A <i>Mycobacterium tuberculosis</i> Specific IgG3 Signature of Recurrent Tuberculosis. <i>Frontiers in Immunology</i> , 2021, 12, 729186.	2.2	8
80	Fab and Fc contribute to maximal protection against SARS-CoV-2 following NVX-CoV2373 subunit vaccine with Matrix-M vaccination. <i>Cell Reports Medicine</i> , 2021, 2, 100405.	3.3	110
81	Coronavirus disease 2019 vaccine response in pregnant and lactating women: a cohort study. <i>American Journal of Obstetrics and Gynecology</i> , 2021, 225, 303.e1-303.e17.	0.7	471
82	Early cross-coronavirus reactive signatures of humoral immunity against COVID-19. <i>Science Immunology</i> , 2021, 6, eabj2901.	5.6	67
83	Dissecting strategies to tune the therapeutic potential of SARS-CoV-2-specific monoclonal antibody CR3022. <i>JCI Insight</i> , 2021, 6, .	2.3	34
84	Correlates of protection against SARS-CoV-2 in rhesus macaques. <i>Nature</i> , 2021, 590, 630-634.	13.7	995
85	Vi-specific serological correlates of protection for typhoid fever. <i>Journal of Experimental Medicine</i> , 2021, 218, .	4.2	45
86	Selective functional antibody transfer into the breastmilk after SARS-CoV-2 infection. <i>Cell Reports</i> , 2021, 37, 109959.	2.9	23
87	COVID-19 mRNA vaccines drive differential antibody Fc-functional profiles in pregnant, lactating, and nonpregnant women. <i>Science Translational Medicine</i> , 2021, 13, eabi8631.	5.8	80
88	Differential Kinetics of Immune Responses Elicited by Covid-19 Vaccines. <i>New England Journal of Medicine</i> , 2021, 385, 2010-2012.	13.9	228
89	Maternal SARS-CoV-2 infection elicits sexually dimorphic placental immune responses. <i>Science Translational Medicine</i> , 2021, 13, eabi7428.	5.8	84
90	Diverse antiviral IgG effector activities are predicted by unique biophysical antibody features. <i>Retrovirology</i> , 2021, 18, 35.	0.9	7

#	ARTICLE	IF	CITATIONS
91	Epidemiological and Immunological Features of Obesity and SARS-CoV-2. <i>Viruses</i> , 2021, 13, 2235.	1.5	15
92	Functional convalescent plasma antibodies and pre-infusion titers shape the early severe COVID-19 immune response. <i>Nature Communications</i> , 2021, 12, 6853.	5.8	41
93	Robust IgM responses following intravenous vaccination with Bacille Calmette-Guérin associate with prevention of Mycobacterium tuberculosis infection in macaques. <i>Nature Immunology</i> , 2021, 22, 1515-1523.	7.0	55
94	Sequence and vector shapes vaccine induced antibody effector functions in HIV vaccine trials. <i>PLoS Pathogens</i> , 2021, 17, e1010016.	2.1	1
95	Reduced antibody activity against SARS-CoV-2 B.1.617.2 delta virus in serum of mRNA-vaccinated individuals receiving tumor necrosis factor- α inhibitors. <i>Med</i> , 2021, 2, 1327-1341.e4.	2.2	31
96	Delayed fractional dosing with RTS,S/AS01 improves humoral immunity to malaria via a balance of polyfunctional NANP6- and Pf16-specific antibodies. <i>Med</i> , 2021, 2, 1269-1286.e9.	2.2	17
97	A particulate saponin/TLR agonist vaccine adjuvant alters lymph flow and modulates adaptive immunity. <i>Science Immunology</i> , 2021, 6, eabf1152.	5.6	63
98	Passive Transfer of Vaccine-Elicited Antibodies Protects against SIV in Rhesus Macaques. <i>Cell</i> , 2020, 183, 185-196.e14.	13.5	25
99	Viral epitope profiling of COVID-19 patients reveals cross-reactivity and correlates of severity. <i>Science</i> , 2020, 370, .	6.0	511
100	Antibodies targeting epitopes on the cell-surface form of NS1 protect against Zika virus infection during pregnancy. <i>Nature Communications</i> , 2020, 11, 5278.	5.8	30
101	Persistence and decay of human antibody responses to the receptor binding domain of SARS-CoV-2 spike protein in COVID-19 patients. <i>Science Immunology</i> , 2020, 5, .	5.6	561
102	Single-shot Ad26 vaccine protects against SARS-CoV-2 in rhesus macaques. <i>Nature</i> , 2020, 586, 583-588.	13.7	765
103	Mining for humoral correlates of HIV control and latent reservoir size. <i>PLoS Pathogens</i> , 2020, 16, e1008868.	2.1	19
104	An observational study identifying highly tuberculosis-exposed, HIV-1-positive but persistently TB, tuberculin and IGRA negative persons with M. tuberculosis specific antibodies in Cape Town, South Africa. <i>EBioMedicine</i> , 2020, 61, 103053.	2.7	22
105	Loss of Bcl-6-Expressing T Follicular Helper Cells and Germinal Centers in COVID-19. <i>Cell</i> , 2020, 183, 143-157.e13.	13.5	599
106	Persistence and Evolution of SARS-CoV-2 in an Immunocompromised Host. <i>New England Journal of Medicine</i> , 2020, 383, 2291-2293.	13.9	1,069
107	Tracking the Trajectory of Functional Humoral Immune Responses Following Acute HIV Infection. <i>Frontiers in Immunology</i> , 2020, 11, 1744.	2.2	4
108	Dissecting the antibody-OME: past, present, and future. <i>Current Opinion in Immunology</i> , 2020, 65, 89-96.	2.4	12

#	ARTICLE	IF	CITATIONS
109	Mapping functional humoral correlates of protection against malaria challenge following RTS,S/AS01 vaccination. <i>Science Translational Medicine</i> , 2020, 12, .	5.8	100
110	Integrated pipeline for the accelerated discovery of antiviral antibody therapeutics. <i>Nature Biomedical Engineering</i> , 2020, 4, 1030-1043.	11.6	46
111	Distinct Early Serological Signatures Track with SARS-CoV-2 Survival. <i>Immunity</i> , 2020, 53, 524-532.e4.	6.6	334
112	SARS-CoV-2-specific ELISA development. <i>Journal of Immunological Methods</i> , 2020, 484-485, 112832.	0.6	77
113	Mucosal Therapy of Multi-Drug Resistant Tuberculosis With IgA and Interferon- β . <i>Frontiers in Immunology</i> , 2020, 11, 582833.	2.2	19
114	SARS-CoV-2 viral load is associated with increased disease severity and mortality. <i>Nature Communications</i> , 2020, 11, 5493.	5.8	702
115	Ad26 vaccine protects against SARS-CoV-2 severe clinical disease in hamsters. <i>Nature Medicine</i> , 2020, 26, 1694-1700.	15.2	275
116	Evolution of Early SARS-CoV-2 and Cross-Coronavirus Immunity. <i>MSphere</i> , 2020, 5, .	1.3	38
117	Modified vaccinia Ankara vaccine expressing Marburg virus-like particles protects guinea pigs from lethal Marburg virus infection. <i>Npj Vaccines</i> , 2020, 5, 78.	2.9	10
118	Ultrasensitive high-resolution profiling of early seroconversion in patients with COVID-19. <i>Nature Biomedical Engineering</i> , 2020, 4, 1180-1187.	11.6	110
119	High Seroprevalence of Anti-SARS-CoV-2 Antibodies in Chelsea, Massachusetts. <i>Journal of Infectious Diseases</i> , 2020, 222, 1955-1959.	1.9	72
120	Pediatric Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2): Clinical Presentation, Infectivity, and Immune Responses. <i>Journal of Pediatrics</i> , 2020, 227, 45-52.e5.	0.9	288
121	Targeting HIV Env immunogens to B cell follicles in nonhuman primates through immune complex or protein nanoparticle formulations. <i>Npj Vaccines</i> , 2020, 5, 72.	2.9	39
122	HIV Antibody Fc N-Linked Glycosylation Is Associated with Viral Rebound. <i>Cell Reports</i> , 2020, 33, 108502.	2.9	19
123	Quick COVID-19 Healers Sustain Anti-SARS-CoV-2 Antibody Production. <i>Cell</i> , 2020, 183, 1496-1507.e16.	13.5	182
124	Compromised Humoral Functional Evolution Tracks with SARS-CoV-2 Mortality. <i>Cell</i> , 2020, 183, 1508-1519.e12.	13.5	263
125	SARS-CoV-2 infection protects against rechallenge in rhesus macaques. <i>Science</i> , 2020, 369, 812-817.	6.0	789
126	DNA vaccine protection against SARS-CoV-2 in rhesus macaques. <i>Science</i> , 2020, 369, 806-811.	6.0	978

#	ARTICLE	IF	CITATIONS
127	Survivors of Ebola Virus Disease Develop Polyfunctional Antibody Responses. <i>Journal of Infectious Diseases</i> , 2020, 221, 156-161.	1.9	35
128	Co-immunization of DNA and Protein in the Same Anatomical Sites Induces Superior Protective Immune Responses against SHIV Challenge. <i>Cell Reports</i> , 2020, 31, 107624.	2.9	43
129	Dissecting antibody-mediated protection against SARS-CoV-2. <i>Nature Reviews Immunology</i> , 2020, 20, 392-394.	10.6	209
130	Distinct neutralizing antibody correlates of protection among related Zika virus vaccines identify a role for antibody quality. <i>Science Translational Medicine</i> , 2020, 12, .	5.8	30
131	Distinct Human NK Cell Phenotypes and Functional Responses to <i>Mycobacterium tuberculosis</i> in Adults From TB Endemic and Non-endemic Regions. <i>Frontiers in Cellular and Infection Microbiology</i> , 2020, 10, 120.	1.8	27
132	Hinge length contributes to the phagocytic activity of HIV-specific IgG1 and IgG3 antibodies. <i>PLoS Pathogens</i> , 2020, 16, e1008083.	2.1	50
133	Understanding the role of antibody glycosylation through the lens of severe viral and bacterial diseases. <i>Glycobiology</i> , 2020, 30, 241-253.	1.3	85
134	Antibody Fc Glycosylation Discriminates Between Latent and Active Tuberculosis. <i>Journal of Infectious Diseases</i> , 2020, 222, 2093-2102.	1.9	47
135	Comparison of shortened mosaic HIV-1 vaccine schedules: a randomised, double-blind, placebo-controlled phase 1 trial (IPCAVD010/HPX1002) and a preclinical study in rhesus monkeys (NHP) Tj ETQq1 2.0.7843149gBT /O	2.0	149
136	Maternal determinants of infant immunity: Implications for effective immunization and maternal-child health. <i>Vaccine</i> , 2020, 38, 4491-4494.	1.7	3
137	Analysis of a Therapeutic Antibody Cocktail Reveals Determinants for Cooperative and Broad Ebola Virus Neutralization. <i>Immunity</i> , 2020, 52, 388-403.e12.	6.6	71
138	Non-neutralizing Antibodies from a Marburg Infection Survivor Mediate Protection by Fc-Effector Functions and by Enhancing Efficacy of Other Antibodies. <i>Cell Host and Microbe</i> , 2020, 27, 976-991.e11.	5.1	43
139	Assessment of Maternal and Neonatal SARS-CoV-2 Viral Load, Transplacental Antibody Transfer, and Placental Pathology in Pregnancies During the COVID-19 Pandemic. <i>JAMA Network Open</i> , 2020, 3, e2030455.	2.8	315
140	HIV Is Associated with Modified Humoral Immune Responses in the Setting of HIV/TB Coinfection. <i>MSphere</i> , 2020, 5, .	1.3	14
141	Distinct Immunoglobulin Fc Glycosylation Patterns Are Associated with Disease Nonprogression and Broadly Neutralizing Antibody Responses in Children with HIV Infection. <i>MSphere</i> , 2020, 5, .	1.3	7
142	Protein-based, but not viral vector alone, HIV vaccine boosting drives an IgG1-biased polyfunctional humoral immune response. <i>JCI Insight</i> , 2020, 5, .	2.3	12
143	IgG3 collaborates with IgG1 and IgA to recruit effector function in RV144 vaccinees. <i>JCI Insight</i> , 2020, 5, .	2.3	12
144	RV144 HIV-1 vaccination impacts post-infection antibody responses. <i>PLoS Pathogens</i> , 2020, 16, e1009101.	2.1	13

#	ARTICLE	IF	CITATIONS
145	A high-throughput, bead-based, antigen-specific assay to assess the ability of antibodies to induce complement activation. <i>Journal of Immunological Methods</i> , 2019, 473, 112630.	0.6	149
146	Neutralizing antibodies against Mayaro virus require Fc effector functions for protective activity. <i>Journal of Experimental Medicine</i> , 2019, 216, 2282-2301.	4.2	51
147	Fc Characteristics Mediate Selective Placental Transfer of IgG in HIV-Infected Women. <i>Cell</i> , 2019, 178, 190-201.e11.	13.5	93
148	A vaccine-induced gene expression signature correlates with protection against SIV and HIV in multiple trials. <i>Science Translational Medicine</i> , 2019, 11, .	5.8	26
149	A Molecular Signature in Blood Reveals a Role for p53 in Regulating Malaria-Induced Inflammation. <i>Immunity</i> , 2019, 51, 750-765.e10.	6.6	67
150	A Sample-Sparing Multiplexed ADCP Assay. <i>Frontiers in Immunology</i> , 2019, 10, 1851.	2.2	42
151	Multi-isotype Glycoproteomic Characterization of Serum Antibody Heavy Chains Reveals Isotype- and Subclass-Specific N-Glycosylation Profiles. <i>Molecular and Cellular Proteomics</i> , 2019, 18, 686-703.	2.5	44
152	Antibody Fabâ€¢Fc properties outperform titer in predictive models of <sc>SIV</sc> vaccineâ€¢induced protection. <i>Molecular Systems Biology</i> , 2019, 15, e8747.	3.2	17
153	A versatile high-throughput assay to characterize antibody-mediated neutrophil phagocytosis. <i>Journal of Immunological Methods</i> , 2019, 471, 46-56.	0.6	124
154	Outflanking immunodominance to target subdominant broadly neutralizing epitopes. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019, 116, 13474-13479.	3.3	57
155	A Case for Antibodies as Mechanistic Correlates of Immunity in Tuberculosis. <i>Frontiers in Immunology</i> , 2019, 10, 996.	2.2	42
156	Fc Glycan-Mediated Regulation of Placental Antibody Transfer. <i>Cell</i> , 2019, 178, 202-215.e14.	13.5	157
157	IFN-Î³-independent immune markers of Mycobacterium tuberculosis exposure. <i>Nature Medicine</i> , 2019, 25, 977-987.	15.2	186
158	Expansion of Stem Cell-Like CD4⁺Memory T Cells during Acute HIV-1 Infection Is Linked to Rapid Disease Progression. <i>Journal of Virology</i> , 2019, 93, .	1.5	11
159	The Antibodiomeâ€¢ Mapping the Humoral Immune Response to HIV. <i>Current HIV/AIDS Reports</i> , 2019, 16, 169-179.	1.1	13
160	Prediction of VRC01 neutralization sensitivity by HIV-1 gp160 sequence features. <i>PLoS Computational Biology</i> , 2019, 15, e1006952.	1.5	25
161	Extra-Neutralizing FcR-Mediated Antibody Functions for a Universal Influenza Vaccine. <i>Frontiers in Immunology</i> , 2019, 10, 440.	2.2	63
162	Optimal therapeutic activity of monoclonal antibodies against chikungunya virus requires Fc-FcÎ³R interaction on monocytes. <i>Science Immunology</i> , 2019, 4, .	5.6	60

#	ARTICLE	IF	CITATIONS
163	ALVAC-HIV B/C candidate HIV vaccine efficacy dependent on neutralization profile of challenge virus and adjuvant dose and type. <i>PLoS Pathogens</i> , 2019, 15, e1008121.	2.1	19
164	Initiation of Antiretroviral Therapy Before Pregnancy Reduces the Risk of Infection-related Hospitalization in Human Immunodeficiency Virus-exposed Uninfected Infants Born in a High-income Country. <i>Clinical Infectious Diseases</i> , 2019, 68, 1193-1203.	2.9	60
165	Sex differences in vaccine-induced humoral immunity. <i>Seminars in Immunopathology</i> , 2019, 41, 239-249.	2.8	284
166	Reply to Slogrove et al. <i>Clinical Infectious Diseases</i> , 2019, 68, 2158-2158.	2.9	2
167	Development of a Human Antibody Cocktail that Deploys Multiple Functions to Confer Pan-Ebolavirus Protection. <i>Cell Host and Microbe</i> , 2019, 25, 39-48.e5.	5.1	83
168	A Two-Antibody Pan-Ebolavirus Cocktail Confers Broad Therapeutic Protection in Ferrets and Nonhuman Primates. <i>Cell Host and Microbe</i> , 2019, 25, 49-58.e5.	5.1	82
169	Sex-Based Differences in Human Immunodeficiency Virus Type 1 Reservoir Activity and Residual Immune Activation. <i>Journal of Infectious Diseases</i> , 2019, 219, 1084-1094.	1.9	73
170	Antibody-Mediated Protective Mechanisms Induced by a Trivalent Parainfluenza Virus-Vectored Ebola Virus Vaccine. <i>Journal of Virology</i> , 2019, 93, .	1.5	13
171	Predicting the broadly neutralizing antibody susceptibility of the HIV reservoir. <i>JCI Insight</i> , 2019, 4, .	2.3	25
172	Selective induction of antibody effector functional responses using MF59-adjuvanted vaccination. <i>Journal of Clinical Investigation</i> , 2019, 130, 662-672.	3.9	50
173	Viral control in chronic HIV-1 subtype C infection is associated with enrichment of p24 IgG1 with Fc effector activity. <i>Aids</i> , 2018, 32, 1207-1217.	1.0	31
174	High-resolution definition of humoral immune response correlates of effective immunity against HIV. <i>Molecular Systems Biology</i> , 2018, 14, e7881.	3.2	37
175	First-in-Human Randomized, Controlled Trial of Mosaic HIV-1 Immunogens Delivered via a Modified Vaccinia Ankara Vector. <i>Journal of Infectious Diseases</i> , 2018, 218, 633-644.	1.9	35
176	Temporal variation in HIV-specific IgG subclass antibodies during acute infection differentiates spontaneous controllers from chronic progressors. <i>Aids</i> , 2018, 32, 443-450.	1.0	35
177	Prevention of tuberculosis in rhesus macaques by a cytomegalovirus-based vaccine. <i>Nature Medicine</i> , 2018, 24, 130-143.	15.2	225
178	Enrichment of high affinity subclasses and glycoforms from serum-derived IgG using Fc γ Rs as affinity ligands. <i>Biotechnology and Bioengineering</i> , 2018, 115, 1265-1278.	1.7	9
179	The Marburgvirus-Neutralizing Human Monoclonal Antibody MR191 Targets a Conserved Site to Block Virus Receptor Binding. <i>Cell Host and Microbe</i> , 2018, 23, 101-109.e4.	5.1	40
180	Optimization and qualification of an Fc Array assay for assessments of antibodies against HIV-1/SIV. <i>Journal of Immunological Methods</i> , 2018, 455, 24-33.	0.6	36

#	ARTICLE	IF	CITATIONS
181	Beyond binding: antibody effector functions in infectious diseases. <i>Nature Reviews Immunology</i> , 2018, 18, 46-61.	10.6	516
182	Vectored delivery of anti-SIV envelope targeting mAb via AAV8 protects rhesus macaques from repeated limiting dose intrarectal swarm SIVsmE660 challenge. <i>PLoS Pathogens</i> , 2018, 14, e1007395.	2.1	37
183	Antibody and TLR7 agonist delay viral rebound in SHIV-infected monkeys. <i>Nature</i> , 2018, 563, 360-364.	13.7	246
184	Antibody-mediated protection against Ebola virus. <i>Nature Immunology</i> , 2018, 19, 1169-1178.	7.0	127
185	Modulation of Vaccine-Induced CD4 T Cell Functional Profiles by Changes in Components of HIV Vaccine Regimens in Humans. <i>Journal of Virology</i> , 2018, 92, .	1.5	7
186	The TLR-4 agonist adjuvant, GLA-SE, improves magnitude and quality of immune responses elicited by the ID93 tuberculosis vaccine: first-in-human trial. <i>Npj Vaccines</i> , 2018, 3, 34.	2.9	135
187	Route of immunization defines multiple mechanisms of vaccine-mediated protection against SIV. <i>Nature Medicine</i> , 2018, 24, 1590-1598.	15.2	129
188	Control of Heterologous Simian Immunodeficiency Virus SIV _{smE660} Infection by DNA and Protein Coimmunization Regimens Combined with Different Toll-Like-Receptor-4-Based Adjuvants in Macaques. <i>Journal of Virology</i> , 2018, 92, .	1.5	39
189	Analysis of Complement-Mediated Lysis of Simian Immunodeficiency Virus (SIV) and SIV-Infected Cells Reveals Sex Differences in Vaccine-Induced Immune Responses in Rhesus Macaques. <i>Journal of Virology</i> , 2018, 92, .	1.5	26
190	Evaluation of a mosaic HIV-1 vaccine in a multicentre, randomised, double-blind, placebo-controlled, phase 1/2a clinical trial (APPROACH) and in rhesus monkeys (NHP 13-19). <i>Lancet, The</i> , 2018, 392, 232-243.	6.3	269
191	Fully Human Immunoglobulin G From Transchromosomal Bovines Treats Nonhuman Primates Infected With Ebola Virus Makona Isolate. <i>Journal of Infectious Diseases</i> , 2018, 218, S636-S648.	1.9	19
192	Multifunctional Pan-ebolavirus Antibody Recognizes a Site of Broad Vulnerability on the Ebolavirus Glycoprotein. <i>Immunity</i> , 2018, 49, 363-374.e10.	6.6	61
193	Immune Correlate-Guided HIV Vaccine Design. <i>Cell Host and Microbe</i> , 2018, 24, 25-33.	5.1	44
194	Antigen-specific antibody Fc glycosylation enhances humoral immunity via the recruitment of complement. <i>Science Immunology</i> , 2018, 3, .	5.6	78
195	Exploiting glycan topography for computational design of Env glycoprotein antigenicity. <i>PLoS Computational Biology</i> , 2018, 14, e1006093.	1.5	19
196	Neonate-omics: Charting the Unknown Immune Response in Early Life. <i>Cell</i> , 2018, 174, 1051-1053.	13.5	14
197	Asymmetric antiviral effects of ebolavirus antibodies targeting glycoprotein stem and glycan cap. <i>PLoS Pathogens</i> , 2018, 14, e1007204.	2.1	16
198	A Role for Fc Function in Therapeutic Monoclonal Antibody-Mediated Protection against Ebola Virus. <i>Cell Host and Microbe</i> , 2018, 24, 221-233.e5.	5.1	182

#	ARTICLE	IF	CITATIONS
199	Systematic Analysis of Monoclonal Antibodies against Ebola Virus GP Defines Features that Contribute to Protection. <i>Cell</i> , 2018, 174, 938-952.e13.	13.5	173
200	Antibody glycosylation in inflammation, disease and vaccination. <i>Seminars in Immunology</i> , 2018, 39, 102-110.	2.7	131
201	HIV-specific Fc effector function early in infection predicts the development of broadly neutralizing antibodies. <i>PLoS Pathogens</i> , 2018, 14, e1006987.	2.1	71
202	Immunological mechanisms of human resistance to persistent <i>Mycobacterium tuberculosis</i> infection. <i>Nature Reviews Immunology</i> , 2018, 18, 575-589.	10.6	241
203	ADCC-Mediated CD56dim NK Cell Responses Are Associated with Early HBsAg Clearance in Acute HBV Infection. <i>Pathogens and Immunity</i> , 2018, 3, 2.	1.4	22
204	Systems serology for evaluation of HIV vaccine trials. <i>Immunological Reviews</i> , 2017, 275, 262-270.	2.8	69
205	Multiplexed Fc array for evaluation of antigen-specific antibody effector profiles. <i>Journal of Immunological Methods</i> , 2017, 443, 33-44.	0.6	158
206	Preservation of Peripheral T Follicular Helper Cell Function in HIV Controllers. <i>Journal of Virology</i> , 2017, 91, .	1.5	32
207	The HIV-1 Glycan Shield: Strategically Placed Kinks in the Armor Improve Antigen Design. <i>Cell Reports</i> , 2017, 19, 669-670.	2.9	7
208	Pentavalent HIV-1 vaccine protects against simian-human immunodeficiency virus challenge. <i>Nature Communications</i> , 2017, 8, 15711.	5.8	137
209	The Immunoregulatory Roles of Antibody Glycosylation. <i>Trends in Immunology</i> , 2017, 38, 358-372.	2.9	259
210	Transfer of maternal immunity and programming of the newborn immune system. <i>Seminars in Immunopathology</i> , 2017, 39, 605-613.	2.8	110
211	Differential Inhibitory Receptor Expression on T Cells Delineates Functional Capacities in Chronic Viral Infection. <i>Journal of Virology</i> , 2017, 91, .	1.5	39
212	Opportunities to exploit antibody glycosylation in vaccination. <i>Future Virology</i> , 2017, 12, 325-328.	0.9	2
213	Virus-driven Inflammation Is Associated With the Development of bNAbs in Spontaneous Controllers of HIV. <i>Clinical Infectious Diseases</i> , 2017, 64, 1098-1104.	2.9	36
214	Innate transcriptional effects by adjuvants on the magnitude, quality, and durability of HIV envelope responses in NHPs. <i>Blood Advances</i> , 2017, 1, 2329-2342.	2.5	90
215	Plasma CXCL13 but Not B Cell Frequencies in Acute HIV Infection Predicts Emergence of Cross-Neutralizing Antibodies. <i>Frontiers in Immunology</i> , 2017, 8, 1104.	2.2	45
216	Systems serology: profiling vaccine induced humoral immunity against HIV. <i>Retrovirology</i> , 2017, 14, 57.	0.9	75

#	ARTICLE	IF	CITATIONS
217	Polyfunctional HIV-Specific Antibody Responses Are Associated with Spontaneous HIV Control. <i>PLoS Pathogens</i> , 2016, 12, e1005315.	2.1	220
218	Diversity of Antiviral IgG Effector Activities Observed in HIV-Infected and Vaccinated Subjects. <i>Journal of Immunology</i> , 2016, 197, 4603-4612.	0.4	44
219	HLA-C levels impact natural killer cell subset distribution and function. <i>Human Immunology</i> , 2016, 77, 1147-1153.	1.2	21
220	Protective efficacy of multiple vaccine platforms against Zika virus challenge in rhesus monkeys. <i>Science</i> , 2016, 353, 1129-1132.	6.0	461
221	IgG Binding Characteristics of Rhesus Macaque Fc γ 3R. <i>Journal of Immunology</i> , 2016, 197, 2936-2947.	0.4	43
222	A Functional Role for Antibodies in Tuberculosis. <i>Cell</i> , 2016, 167, 433-443.e14.	13.5	461
223	Ad26/MVA therapeutic vaccination with TLR7 stimulation in SIV-infected rhesus monkeys. <i>Nature</i> , 2016, 540, 284-287.	13.7	246
224	Modulating Antibody Functionality in Infectious Disease and Vaccination. <i>Trends in Molecular Medicine</i> , 2016, 22, 969-982.	3.5	71
225	Multiplexed Affinity-Based Separation of Proteins and Cells Using Inertial Microfluidics. <i>Scientific Reports</i> , 2016, 6, 23589.	1.6	62
226	Broadly Neutralizing Antibodies: Magic Bullets against HIV?. <i>Immunity</i> , 2016, 44, 1253-1254.	6.6	3
227	Adjuvant-dependent innate and adaptive immune signatures of risk of SIVmac251 acquisition. <i>Nature Medicine</i> , 2016, 22, 762-770.	15.2	197
228	NK Cells in HIV Disease. <i>Current HIV/AIDS Reports</i> , 2016, 13, 85-94.	1.1	114
229	Circulating HIV-Specific Interleukin-21+CD4+ T Cells Represent Peripheral Tfh Cells with Antigen-Dependent Helper Functions. <i>Immunity</i> , 2016, 44, 167-178.	6.6	104
230	A Drug-Free Zone in Lymph Nodes as a Safe Haven for HIV. <i>Cell Host and Microbe</i> , 2016, 19, 275-276.	5.1	16
231	Enhanced binding of antibodies generated during chronic HIV infection to mucus component MUC16. <i>Mucosal Immunology</i> , 2016, 9, 1549-1558.	2.7	47
232	Pan-ebolavirus and Pan-filovirus Mouse Monoclonal Antibodies: Protection against Ebola and Sudan Viruses. <i>Journal of Virology</i> , 2016, 90, 266-278.	1.5	92
233	Broadly Neutralizing Antibodies Against HIV: New Insights to Inform Vaccine Design. <i>Annual Review of Medicine</i> , 2016, 67, 185-200.	5.0	38
234	Antigen-Specific Antibody Glycosylation Is Regulated via Vaccination. <i>PLoS Pathogens</i> , 2016, 12, e1005456.	2.1	124

#	ARTICLE	IF	CITATIONS
235	Prospects for engineering HIV-specific antibodies for enhanced effector function and half-life. <i>Current Opinion in HIV and AIDS</i> , 2015, 10, 160-169.	1.5	21
236	Modest Attenuation of HIV-1 Vpu Alleles Derived from Elite Controller Plasma. <i>PLoS ONE</i> , 2015, 10, e0120434.	1.1	13
237	Selection of an HLA-C*03:04-Restricted HIV-1 p24 Gag Sequence Variant Is Associated with Viral Escape from KIR2DL3+ Natural Killer Cells: Data from an Observational Cohort in South Africa. <i>PLoS Medicine</i> , 2015, 12, e1001900.	3.9	66
238	Beyond adjuvants: Antagonizing inflammation to enhance vaccine immunity. <i>Vaccine</i> , 2015, 33, B55-B59.	1.7	35
239	A method for high-throughput, sensitive analysis of IgG Fc and Fab glycosylation by capillary electrophoresis. <i>Journal of Immunological Methods</i> , 2015, 417, 34-44.	0.6	95
240	Protective efficacy of adenovirus/protein vaccines against SIV challenges in rhesus monkeys. <i>Science</i> , 2015, 349, 320-324.	6.0	303
241	Machine Learning Methods Enable Predictive Modeling of Antibody Feature:Function Relationships in RV144 Vaccines. <i>PLoS Computational Biology</i> , 2015, 11, e1004185.	1.5	50
242	Cooperativity of HIV-Specific Cytolytic CD4 T Cells and CD8 T Cells in Control of HIV Viremia. <i>Journal of Virology</i> , 2015, 89, 7494-7505.	1.5	70
243	HIV-1 Single-Stranded RNA Induces CXCL13 Secretion in Human Monocytes via TLR7 Activation and Plasmacytoid Dendritic Cell-Derived Type I IFN. <i>Journal of Immunology</i> , 2015, 194, 2769-2775.	0.4	49
244	Dissecting Polyclonal Vaccine-Induced Humoral Immunity against HIV Using Systems Serology. <i>Cell</i> , 2015, 163, 988-998.	13.5	326
245	Microscale purification of antigen-specific antibodies. <i>Journal of Immunological Methods</i> , 2015, 425, 27-36.	0.6	19
246	Exploring the Potential of Monoclonal Antibody Therapeutics for HIV-1 Eradication. <i>AIDS Research and Human Retroviruses</i> , 2015, 31, 13-24.	0.5	46
247	CD39 Expression Identifies Terminally Exhausted CD8+ T Cells. <i>PLoS Pathogens</i> , 2015, 11, e1005177.	2.1	296
248	Chronic HCV Infection Affects the NK Cell Phenotype in the Blood More than in the Liver. <i>PLoS ONE</i> , 2014, 9, e105950.	1.1	29
249	Highly parallel characterization of IgG Fc binding interactions. <i>MAbs</i> , 2014, 6, 915-927.	2.6	72
250	Divergent Antibody Subclass and Specificity Profiles but Not Protective HLA-B Alleles Are Associated with Variable Antibody Effector Function among HIV-1 Controllers. <i>Journal of Virology</i> , 2014, 88, 2799-2809.	1.5	46
251	Dissecting the antibody constant region protective immune parameters in HIV infection. <i>Future Virology</i> , 2014, 9, 397-414.	0.9	8
252	Modulation of RAS Pathways as a Biomarker of Protection against HIV and as a Means to Improve Vaccine Efficacy. <i>AIDS Research and Human Retroviruses</i> , 2014, 30, A99-A99.	0.5	2

#	ARTICLE	IF	CITATIONS
253	Independent evolution of Fc- and Fab-mediated HIV-1-specific antiviral antibody activity following acute infection. <i>European Journal of Immunology</i> , 2014, 44, 2925-2937.	1.6	44
254	Polyfunctional Fc-Effector Profiles Mediated by IgG Subclass Selection Distinguish RV144 and VAX003 Vaccines. <i>Science Translational Medicine</i> , 2014, 6, 228ra38.	5.8	367
255	Identification of antibody glycosylation structures that predict monoclonal antibody Fc-effector function. <i>Aids</i> , 2014, 28, 2523-2530.	1.0	108
256	Effect of Human Immunodeficiency Virus Infection on Plasma Bactericidal Activity against <i>Salmonella enterica</i> Serovar Typhimurium. <i>Vaccine Journal</i> , 2014, 21, 1437-1442.	3.2	6
257	Emergence of Individual HIV-Specific CD8 T Cell Responses during Primary HIV-1 Infection Can Determine Long-Term Disease Outcome. <i>Journal of Virology</i> , 2014, 88, 12793-12801.	1.5	30
258	Early Preservation of CXCR5 ⁺ PD-1 ⁺ Helper T Cells and B Cell Activation Predict the Breadth of Neutralizing Antibody Responses in Chronic HIV-1 Infection. <i>Journal of Virology</i> , 2014, 88, 13310-13321.	1.5	94
259	An antibody tag-team: driving neutralization through escape. <i>Trends in Immunology</i> , 2014, 35, 403-405.	2.9	0
260	KIR2DL3+NKG2A ^{hi} natural killer cells are associated with protection from productive hepatitis C virus infection in people who inject drugs. <i>Journal of Hepatology</i> , 2014, 61, 475-481.	1.8	38
261	Lack of Protection following Passive Transfer of Polyclonal Highly Functional Low-Dose Non-Neutralizing Antibodies. <i>PLoS ONE</i> , 2014, 9, e97229.	1.1	59
262	KIR2DS4 Promotes HIV-1 Pathogenesis: New Evidence from Analyses of Immunogenetic Data and Natural Killer Cell Function. <i>PLoS ONE</i> , 2014, 9, e99353.	1.1	28
263	Protective Efficacy of a Global HIV-1 Mosaic Vaccine against Heterologous SHIV Challenges in Rhesus Monkeys. <i>Cell</i> , 2013, 155, 531-539.	13.5	334
264	Characterization of Humoral and Cellular Immune Responses Elicited by a Recombinant Adenovirus Serotype 26 HIV-1 Env Vaccine in Healthy Adults (IPCAVD 001). <i>Journal of Infectious Diseases</i> , 2013, 207, 248-256.	1.9	98
265	Enhanced Phagocytic Activity of HIV-Specific Antibodies Correlates with Natural Production of Immunoglobulins with Skewed Affinity for FcγR2a and FcγR2b. <i>Journal of Virology</i> , 2013, 87, 5468-5476.	1.5	94
266	Natural variation in Fc glycosylation of HIV-specific antibodies impacts antiviral activity. <i>Journal of Clinical Investigation</i> , 2013, 123, 2183-2192.	3.9	310
267	Opportunities to Exploit Non-Neutralizing HIV-Specific Antibody Activity. <i>Current HIV Research</i> , 2013, 11, 365-377.	0.2	37
268	Innate Immune Control of HIV. <i>Cold Spring Harbor Perspectives in Medicine</i> , 2012, 2, a007070-a007070.	2.9	62
269	A Nonfucosylated Variant of the anti-HIV-1 Monoclonal Antibody b12 Has Enhanced FcγRIIIa-Mediated Antiviral Activity <i>In Vitro</i> but Does Not Improve Protection against Mucosal SHIV Challenge in Macaques. <i>Journal of Virology</i> , 2012, 86, 6189-6196.	1.5	110
270	A 17q12 Allele Is Associated with Altered NK Cell Subsets and Function. <i>Journal of Immunology</i> , 2012, 188, 3315-3322.	0.4	24

#	ARTICLE	IF	CITATIONS
271	Emerging Concepts on the Role of Innate Immunity in the Prevention and Control of HIV Infection. <i>Annual Review of Medicine</i> , 2012, 63, 113-130.	5.0	64
272	High-throughput, multiplexed IgG subclassing of antigen-specific antibodies from clinical samples. <i>Journal of Immunological Methods</i> , 2012, 386, 117-123.	0.6	197
273	KIR/HLA: Genetic Clues for a Role of NK Cells in the Control of HIV. <i>Advances in Experimental Medicine and Biology</i> , 2011, 780, 27-36.	0.8	10
274	HIV-1 adaptation to NK-cell-mediated immune pressure. <i>Nature</i> , 2011, 476, 96-100.	13.7	310
275	Mutiny or scrutiny: NK cell modulation of DC function in HIV-1 infection. <i>Trends in Immunology</i> , 2011, 32, 219-224.	2.9	26
276	Reduced frequencies of NKp30+NKp46+, CD161+, and NKG2D+ NK cells in acute HCV infection may predict viral clearance. <i>Journal of Hepatology</i> , 2011, 55, 278-288.	1.8	118
277	Copy Number Variation of KIR Genes Influences HIV-1 Control. <i>PLoS Biology</i> , 2011, 9, e1001208.	2.6	132
278	Natural killer cells in spontaneous control of HIV infection. <i>Current Opinion in HIV and AIDS</i> , 2011, 6, 208-213.	1.5	22
279	Determining the Phagocytic Activity of Clinical Antibody Samples. <i>Journal of Visualized Experiments</i> , 2011, , e3588.	0.2	26
280	A robust, high-throughput assay to determine the phagocytic activity of clinical antibody samples. <i>Journal of Immunological Methods</i> , 2011, 366, 8-19.	0.6	393
281	Decreased Fc receptor expression on innate immune cells is associated with impaired antibody-mediated cellular phagocytic activity in chronically HIV-1 infected individuals. <i>Virology</i> , 2011, 415, 160-167.	1.1	90
282	Early viral replication in lymph nodes provides HIV with a means by which to escape NK cell-mediated control. <i>European Journal of Immunology</i> , 2011, 41, 2729-2740.	1.6	37
283	Characteristics of the Earliest Cross-Neutralizing Antibody Response to HIV-1. <i>PLoS Pathogens</i> , 2011, 7, e1001251.	2.1	276
284	KIR Polymorphisms Modulate Peptide-Dependent Binding to an MHC Class I Ligand with a Bw6 Motif. <i>PLoS Pathogens</i> , 2011, 7, e1001316.	2.1	60
285	The Humoral Response to HIV-1: New Insights, Renewed Focus. <i>Journal of Infectious Diseases</i> , 2010, 202, S315-S322.	1.9	45
286	IL-10 induces aberrant deletion of dendritic cells by natural killer cells in the context of HIV infection. <i>Journal of Clinical Investigation</i> , 2010, 120, 1905-1913.	3.9	74
287	HLA Class I Subtype-Dependent Expansion of KIR3DS1 ⁺ and KIR3DL1 ⁺ NK Cells during Acute Human Immunodeficiency Virus Type 1 Infection. <i>Journal of Virology</i> , 2009, 83, 6798-6805.	1.5	170
288	Matrix Metalloprotease Inhibitors Restore Impaired NK Cell-Mediated Antibody-Dependent Cellular Cytotoxicity in Human Immunodeficiency Virus Type 1 Infection. <i>Journal of Virology</i> , 2009, 83, 8705-8712.	1.5	105

#	ARTICLE	IF	CITATIONS
289	Sex differences in the Toll-like receptor-mediated response of plasmacytoid dendritic cells to HIV-1. <i>Nature Medicine</i> , 2009, 15, 955-959.	15.2	523
290	Challenges facing young investigators. <i>IAVI Report: Newsletter on International AIDS Vaccine Research</i> , 2009, 13, 14-7.	0.0	0
291	Ligand-Independent Exhaustion of Killer Immunoglobulin-Like Receptor-Positive CD8 ⁺ T Cells in Human Immunodeficiency Virus Type 1 Infection. <i>Journal of Virology</i> , 2008, 82, 9668-9677.	1.5	39
292	Upregulation of PD-L1 on monocytes and dendritic cells by HIV-1 derived TLR ligands. <i>Aids</i> , 2008, 22, 655-658.	1.0	89
293	Antigen Load and Viral Sequence Diversification Determine the Functional Profile of HIV-1-Specific CD8 ⁺ T Cells. <i>PLoS Medicine</i> , 2008, 5, e100.	3.9	205
294	Single-Stranded RNA Derived from HIV-1 Serves as a Potent Activator of NK Cells. <i>Journal of Immunology</i> , 2007, 178, 7658-7666.	0.4	92
295	Recognition of a Defined Region within p24 Gag by CD8 ⁺ T Cells during Primary Human Immunodeficiency Virus Type 1 Infection in Individuals Expressing Protective HLA Class I Alleles. <i>Journal of Virology</i> , 2007, 81, 7725-7731.	1.5	116
296	Evolution of Innate and Adaptive Effector Cell Functions during Acute HIV-1 Infection. <i>Journal of Infectious Diseases</i> , 2007, 195, 1452-1460.	1.9	123
297	Differential natural killer cell-mediated inhibition of HIV-1 replication based on distinct KIR/HLA subtypes. <i>Journal of Experimental Medicine</i> , 2007, 204, 3027-3036.	4.2	413
298	Low perforin and elevated SHIP-1 expression is associated with functional anergy of natural killer cells in chronic HIV-1 infection. <i>Aids</i> , 2006, 20, 1549-1551.	1.0	28
299	NK Cell Function in HIV-1 Infection. <i>Current Molecular Medicine</i> , 2006, 6, 621-629.	0.6	43
300	Sequential deregulation of NK cell subset distribution and function starting in acute HIV-1 infection. <i>Blood</i> , 2005, 106, 3366-3369.	0.6	314
301	Increased Natural Killer Cell Activity in Viremic HIV-1 Infection. <i>Journal of Immunology</i> , 2004, 173, 5305-5311.	0.4	128
302	Loss of HIV-1-specific CD8 ⁺ T Cell Proliferation after Acute HIV-1 Infection and Restoration by Vaccine-induced HIV-1-specific CD4 ⁺ T Cells. <i>Journal of Experimental Medicine</i> , 2004, 200, 701-712.	4.2	314
303	CD107a as a functional marker for the identification of natural killer cell activity. <i>Journal of Immunological Methods</i> , 2004, 294, 15-22.	0.6	1,238
304	HIV-1-specific cytotoxicity is preferentially mediated by a subset of CD8 ⁺ T cells producing both interferon- γ and tumor necrosis factor- α . <i>Blood</i> , 2004, 104, 487-494.	0.6	124
305	Longitudinal Assessment of Changes in HIV-Specific Effector Activity in HIV-Infected Patients Starting Highly Active Antiretroviral Therapy in Primary Infection. <i>Journal of Immunology</i> , 2003, 171, 477-488.	0.4	45
306	Immune Responses to Viral Infection. , 0, , 321-350.		1